Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8731 to 8745 of 9128 results

  1. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke [TSID11920]

    In development Reference number: GID-TA11482 Expected publication date: TBC

  2. Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [TSID12194]

    In development Reference number: GID-TA11771 Expected publication date: TBC

  3. Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]

    In development Reference number: GID-TA11781 Expected publication date: TBC

  4. Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]

    In development Reference number: GID-TA11310 Expected publication date: TBC

  5. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6436]

    In development Reference number: GID-TA11567 Expected publication date: TBC

  6. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women [ID1307]

    In development Reference number: GID-TA10261 Expected publication date: TBC

  7. Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091]

    In development Reference number: GID-TA11679 Expected publication date: TBC

  8. Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632]

    In development Reference number: GID-TA11631 Expected publication date: TBC

  9. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [TSID12099]

    In development Reference number: GID-TA11640 Expected publication date: TBC

  10. Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

    Technology appraisal Reference number: TA1180 Published:  16 July 2026

  11. Farco-fill Protect for indwelling urinary catheterisation (MIB121)

    July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.

  12. Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care

    Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 babies' hearing so far with potential to prevent hearing loss in 200 babies annually.

  13. First new NHS treatment in over 20 years recommended for women with resistant ovarian cancer

    The treatment uses a targeted therapy that seeks out a specific protein found on the surface of cancer cells and delivers a cancer-killing medicine directly to them.

  14. Why flexibility is built into everything we do at NICE Advice

    No two products are the same, so no two NICE Advice projects should be either. Andrew Walsh explains how NICE Advice adapts its services to fit your situation.